NICE recommends Gilenya (Novartis) for Multiple Sclerosis

The National Institute of Clinical Evidence (NICE) initially said it was unclear if Gilenya (fingolimod) from Novartis, was any better than existing treatments. It has changed its mind after Novartis presented data showing the benefits of using Gilenya in a subgroup of adults with highly active disease, whose relapses had increased or stayed the same compared with the previous year despite them taking beta interferons. NICE stated that it was now clear that Gilenya was a cost-effective option for these patients, provided Novartis supplied the drug at the discounted price it previously suggested.